Chong Kun Dang is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $17.8B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Chong Kun Dang's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Dupixent | Sanofi / Regeneron | Biosimilar | 2031 | In clinical trials. Phase 1 approved in the EU and UK (Jan 2026) | $17.8B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Chong Kun Dang's share of it.
Chong Kun Dang has a copy in development for Dupixent. Of the 70 makers we follow, 38 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.